Etanercept in severe, recalcitrant psoriasis: clinical response, safety profile and predictors of response based on a single institution's experience

J Eur Acad Dermatol Venereol. 2009 Aug;23(8):979-82. doi: 10.1111/j.1468-3083.2009.03093.x.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Breast Neoplasms / chemically induced
  • Etanercept
  • Female
  • Humans
  • Immunoglobulin G / adverse effects*
  • Immunoglobulin G / therapeutic use*
  • Immunosuppressive Agents / adverse effects*
  • Immunosuppressive Agents / therapeutic use*
  • Lung Neoplasms / chemically induced
  • Male
  • Middle Aged
  • Mouth Neoplasms / chemically induced
  • Psoriasis / drug therapy*
  • Receptors, Tumor Necrosis Factor / therapeutic use*
  • Retrospective Studies
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

  • Immunoglobulin G
  • Immunosuppressive Agents
  • Receptors, Tumor Necrosis Factor
  • Tumor Necrosis Factor-alpha
  • Etanercept